1. Human Malaria {#Section1}
================

Human malaria is caused by unicellular obligate intracellular protozoan parasites of the genus *Plasmodium*. Although malaria was once prevalent throughout most of the world, malaria is currently endemic in the tropical zones with extensions into the sub-tropical regions of Asia, Africa, South and Central America. However, about half of the world\'s population (3.3 billion people) is at risk of malaria in more than 100 countries [@B1]. Four primary species of malaria parasites infect humans: *P. falciparum*, *P. ovale*, *P. malariae* and *P. vivax*. In addition, studies in Southeast Asia have shown that *P. knowlesi*, a malaria parasite that typically involves monkeys as the natural reservoir, can also infect humans, and in some cases, result in fatal disease (reviewed in [@B2]). Malaria due to *P. vivax*, *P. ovale*and *P. malariae* is less severe than that experienced by *P. falciparum* infections and collectively, these three species account for slightly less than 10% of the worldwide malaria cases [@B3]. The most virulent of the human malaria parasites is *P. falciparum* which is responsible for the bulk of the malaria-related morbidity and mortality. *P. falciparum* accounts for 91% of malaria cases worldwide of which the majority (i.e., 86%) occurs in the African region [@B3]. Consistent with the high rate of morbidity within Africa, 90% of the *P. falciparum*-attributable malaria deaths also occur in the African region, primarily sub-Saharan Africa [@B3]. Approximately 247 million malaria infections are estimated annually, resulting in greater than one million deaths, primarily in African children under the age of five [@B1].

2. Clinical Spectrum of *Plasmodium falciparum* Infections {#Section2}
==========================================================

The clinical spectrum of *P. falciparum* malaria in African children encompasses a wide range of pathophysiological derangements and includes multiple organ involvement and systemic disorders. Falciparum malaria ranges from asymptomatic infections to the classic symptoms of malaria (e.g., fever, chills, sweating, headache and muscle aches), which in a sub-population of the cases, results in severe life-threatening complications such as hyperparasitemia, hypoglycemia, hyperlactatemia, kidney failure, metabolic acidosis, cerebral malaria, severe malarial anemia \[SMA, hemoglobin, (Hb)\<5.0 g/dL\], and respiratory distress (RD) [@B4], [@B5]. Although the pathophysiology of malaria is multifactorial and only partially understood, development of a pathogenic versus protective outcome, once an infection occurs, is mediated by host and parasite interactions of which the following appear critically important: endemicity patterns, acquisition of naturally acquired malarial immunity, parasite virulence, multiplication rate, antigenic variation and polymorphic variability in both the host (human) and parasite [@B6]. The age of the individual when they first acquire a malarial infection also plays a significant role in the clinical outcomes of the disease process. For example, children typically display enhanced susceptibility to severe anemia and hypoglycemia, while non-resident malaria-naïve adults are more likely to present with jaundice and progress to renal failure and respiratory distress due to pulmonary edema [@B7].

3. Infant and Childhood Anemia in Developing Nations {#Section3}
====================================================

Although this review will focus primarily on SMA and the innate immune responses that condition the development and outcomes of the disease, it is important to understand the definitions of anemia and the importance of geographic context. A general definition of anemia is a reduction in Hb levels in relation to the age, gender, and physiological status of the individual within a defined geographical context [@B8]. In western countries, anemia is defined by a Hb concentration \<12.0 g/dL, while in developing countries the standard definition of anemia for children \<5 years of age is Hb\<11.0 g/dL [@B8]. Throughout much of the developing world, particularly in regions of sub-Saharan Africa with high rates of malaria and human immunodeficiency virus (HIV), the majority of infants and young children suffer from anemia [@B9]. Anemia in the developing world is largely a product of inadequate feeding practices, frequent infections, and micronutrient deficiencies which culminate in high rates of mortality in infants and young children [@B9]**.**

4. Disease Burden of Severe Malarial Anemia {#Section4}
===========================================

The World Health Organization (WHO) defines SMA as Hb concentrations \<5.0 g/dL (or a hematocrit \<15.0%) in the presence of any density parasitemia [@B5]. SMA is a major public health problem in developing countries where it contributes 3-46% of inpatient pediatric fatalities in referral care facilities [@B10]. Despite efforts aimed at ameliorating the anemia burden, SMA remains an important childhood health burden in sub-Saharan Africa [@B11]. Previous studies in endemic areas of Africa demonstrated that the annual rate of presentation to hospital with SMA was 7.6/1000 in children aged 0-4 years with a case fatality of 9.7% [@B12]. Additional studies illustrate that the risk for SMA peaks at 1 year of age in high (holoendemic) transmission regions and at approximately 2 years of age in areas with moderate and low transmission intensities, such that (in general) the overall risk of SMA decreases with increasing age [@B13]. Multicentre studies indicate that SMA affects 7.5-34% of the African children that acquire malaria with an overall prevalence of 21.2% and case fatality rate of 8.4% [@B14].

5. Etiological Basis of Severe Malarial Anemia {#Section5}
==============================================

The etiology of SMA can include a number of distinct, as well as overlapping features, including lysis of infected and uninfected RBCs [@B15]-[@B18], splenic sequestration of RBCs [@B19], dyserythropoiesis and bone marrow suppression [@B20], [@B21], co-infections with bacteremia, HIV-1, and hookworm [@B22]-[@B26], and chronic transmission of malaria in holoendemic regions. It is important to note that some or all of these factors can culminate in the chronically low Hb values observed in infants and young children residing in holoendemic regions. As such, the degree of parasitemia is typically a poor indicator of malaria disease severity in these locales, especially considering that peripheral parasitemia is a "snapshot" in time of the complex and continuously evolving disease process. However, it is important to stress that high levels of parasitemia, particularly in non-immune individuals, can certainly result in massive lysis and clearance of RBCs, resulting in profound anemia [@B21], [@B27].

6. Impaired Erythropoietic Responses in Severe Malarial Anemia {#Section6}
==============================================================

Although parasite-driven hemolysis will contribute to a reduction in Hb levels in childhood malaria, one of the primary mechanisms responsible for low Hb levels in children with SMA is impaired and/or ineffective erythropoiesis. Loss of appropriate production of erythrocytes translates into a failure in the ability to replenish the reduced pool of erythrocytes due to parasite- and/or anti-malarial-driven hemolysis. Earlier studies demonstrated that there is parenchymal damage of bone marrow, ineffective erythropoiesis, and a reduced rate of erythropoietic proliferation in patients with acute falciparum malaria [@B28]. Subsequent studies in Gambian children demonstrated that SMA was defined by erythroid hyperplasia with dyserythropoiesis [@B6]. Examination of bone marrow from children with SMA revealed hypercellularity, mild to normal erythroid hyperplasia, and abnormal features of late erythroid progenitors, but absence of damage to burst forming unit-erythrocyte (BFU-E) or colony forming unit-erythrocyte (CFU-E) early stages [@B6]. In addition, we have shown that children with SMA have an inefficient reticulocyte production index (RPI) characterized by levels \<2.0 [@B29]. The RPI is a measure of the extent to which the reticulocyte count has risen (or not) in response to the level of anemia [@B30]. Taken together, these investigations demonstrate that suppression of erythropoiesis is a primary cause of severe anemia in children with *P. falciparum* infections.

7. Role of Inflammatory Mediators in Impaired Erythropoiesis {#Section7}
============================================================

Although the precise mechanisms responsible for reduced reticulocyte responses in children with SMA have been somewhat elusive, it is clear that one important cause of reduced erythropoiesis in children with SMA is due to an imbalance in inflammatory mediators. In an attempt to control the parasitemia, the host releases an array of pro- and anti-inflammatory cytokines, chemokines, growth factors, and effector molecules as part of the innate immune response. Depending on the magnitude and timing of inflammatory mediator release, the immune response to malaria can result in either successful control of the parasitemia or alternatively, an inappropriate balance in the inflammatory milieu that can induce damage to the host, including suppression of the erythropoietic response. As such, although malaria is typically viewed as an \'acute\' infection, in regions with high levels of falciparum endemicity, SMA is often a more \'chronic\' condition in which the immunological response to infection drives an inflammatory milieu that can promote suppression of eythropoiesis. This premise is supported by observations showing that persistent childhood *P. falciparum* infections are associated with bone marrow suppression [@B31].

8. Role of Parasitic Products in Stimulating the Innate Immune Response {#Section8}
=======================================================================

There are a number of key parasitic products that drive the innate immune response in the malaria-infected human host, including malarial pigment (hemozoin, Hz), glycosylphosphatidylinositols (GPIs), and parasitic antigens. While it is clear that GPIs, which form the connection between the parasite\'s cellular membrane and external antigens [@B32], as well as an array of parasitic antigens play an important role in activating the immune response, we will focus our discussion on the role of *P. falciparum*-derived Hz (*Pf*Hz) in promoting the host immune response and the potential implications that this process has on suppression of the erythropoietic response. Excellent reviews on the means by which parasite GPIs [@B33] and malarial antigens stimulate the innate immune response can be found elsewhere [@B34].

9. Hemozoin Formation {#Section9}
=====================

The importance of hemozoin in malarial infections was recognized over five decades ago following the discovery that accumulation of phagocytosed malarial pigment in bone marrow produces a brown/black appearance in patients with repeated malaria infections [@B35]. Formation of *Pf*Hz occurs during the intraerythrocytic asexual replication cycle in which *P. falciparum* metabolizes host Hb as a source of amino acids [@B36], [@B37], leaving the iron-rich heme portion designated ferriprotoporphyrin IX (FP-IX). *P. falciparum* then promotes aggregation of the toxic FP-IX molecules, using heme polymerase [@B38], [@B39], into an insoluble product known as *Pf*Hz [@B40]-[@B42]. Once the schizont has gone through replication within the host RBC, the erythrocyte ruptures [@B43], releasing *Pf*Hz along with merozoites, with the newly-formed merozoites infecting other RBCs, and *Pf*Hz being phagocytosed by monocytes/macrophages and neutrophils.

10. Hemozoin Accumulation as a Causal Factor in Suppression of Erythropoiesis {#Section10}
=============================================================================

Accumulation of phagocytes containing malaria pigment in the microvasculature of deep tissues such as the bone marrows of patients with acute malaria was recognized in earlier studies [@B44]. Intraleukocytic malaria pigment is a useful direct diagnostic marker with the amount of phagocytosed pigment being a good indirect measure of the sequestered parasite burden, recent schizogony, and disease severity [@B45]. Studies by others and our group have also found an association between the presence of *Pf*Hz-containing monocytes and suppression of erythropoiesis in children with *P.*falciparum-induced anemia [@B46], [@B47]. In addition, our studies in western Kenya, using multivariate regression analyses, controlling for age, gender, and parasitemia, revealed that elevated levels of pigment-containing monocytes (PCM) were a significant predictor of SMA [@B47]. A recent multi-site study that included 26,296 hospitalized children with *P. falciparum*malaria demonstrated that the percentage of *Pf*Hz-containing monocytes was negatively correlated with hematocrit [@B48]. Additional evidence that *Pf*Hz-containing cells are an important source for promoting erythroid suppression is supported by histological observations of bone marrow in children with SMA, and those dying from malaria, showing that developing erythroid progenitors located within the vicinity of pigmented macrophages have abnormal cellular development [@B46]. Consistent with these observations, we recently demonstrated that elevated levels of *Pf*Hz in monocytes are associated with inefficient erythropoiesis in Kenyan children with malaria [@B49].

11. Severe Malarial Anemia is Characterized by Dysregulation in Innate Inflammatory Mediators {#Section11}
=============================================================================================

One of the primary factors for stimulating the innate immune response to *P. falciparum* is phagocytosis of *Pf*Hz by circulating monocytes and neutrophils, and resident macrophages. One of the primary means by which *Pf*Hz generates an innate immune response is through the toll-like receptors (TLRs). A recent review discussing the role of hemozoin in stimulating the TLRs can be found elsewhere [@B50]. The studies discussed below support a model in which phagocytosis of *Pf*Hz, and the host immune response patterns that ensue following this event, are a critical step in the promotion of the reduced erythroid responses observed in children with SMA (Figure [1](#F1){ref-type="fig"}). Although it is clear that a wealth of important cellular biology is yet to be elucidated about the mechanisms by which phagocytosis of *Pf*Hz shapes the innate immune response, the ability of *Pf*Hz to alter inflammatory mediator profiles is central to its action. However, it is important to note that clarification of strict protective versus pathological roles for inflammatory mediators remains poorly defined and extremely difficult to quantify in human malaria in which manipulation of the biological systems is typically not feasible.

Pro-inflammatory Mediators
--------------------------

A successful type 1 response to malaria requires a well-timed and proportional release of interleukin (IL)-12, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α to minimize parasitemia and preserve erythropoiesis [@B51], [@B52]. The pro-inflammatory phase should be followed by an equally timely abrogation of this response by type 2 cytokines such as IL-10, transforming growth factor (TGF)-β, and IL-4, to avoid inflammatory host damage [@B53].

TNF-α is the molecule typically associated with pathology in malaria and was first hypothesized to be involved in the host immune response to malaria in 1978 [@B54]. Several studies have shown an association between elevated TNF-α levels and morbidity and mortality in individuals with malaria [@B55], [@B56]. However, TNF-α is critical for parasite killing and preventing parasite replication [@B55]-[@B59]. In addition to its direct effects [@B60], [@B61], TNF-α also mediates its effects by inducing production of macrophage migration inhibitory factor (MIF) [@B62], [@B63] and nitric oxide synthase type 2 (NOS2, inducible nitric oxide synthase, iNOS) [@B64], which through generation of nitric oxide (NO) also has direct parasite killing effects [@B65]. TNF-α can also exacerbate inflammation by inducing cyclooxygenase (COX)-2 and subsequently generated effector molecules, such as prostaglandins [@B66]. Many of the signs and symptoms associated with malaria, such as fever, headache, nausea, vomiting, diarrhea, anorexia, myalgias, and thrombocytopenia can be linked to TNF-α [@B67].

IFN-γ is produced by natural killer and αβ-T cells, as well as the regulatory γδ-T cells, during the early phases of the immune response to a malaria infection [@B68]-[@B70]. This prototypical type 1 cytokine is a key molecule for protecting against infection in childhood malaria [@B71] and in non-immune volunteers experimentally infected with malaria [@B72]. The ability to generate IFN-γ from mononuclear cells exposed to asexual malaria parasites has recently been attributed to the significant resistance to *P. falciparum* malaria in the Fulani people of West Africa compared to other tribes in the Mali, Burkina Faso, and Sudan regions [@B73]. Consistent with a protective role, IFN-γ responses to CD8+ T cell epitopes from pre-erythrocytic antigens are associated with higher Hb levels, and reduced prevalence of SMA in Kenyan children [@B74].

Although both TNF-α and IFN-γ appear to play a protective role in children and adults during the early stages of a *P. falciparum* infection through their ability to stimulate monocyte/macrophage activation and aid in controlling parasitemia [@B75], over-production of these innate inflammatory mediators is also associated with anemia [@B76], [@B77]. In addition, persistent macrophage activation is significantly greater in children with complicated malaria [@B78]. Excessive release of IFN-γ and TNF-α, along with NO, also promote enhanced malarial anemia pathogenesis by contributing to bone marrow suppression, dyserythropoiesis, and erythrophagocytosis [@B79].

IL-1 is a potent endogenous pyrogen that promotes an acute inflammatory response and provides a first line of defense against invading pathogens [@B80]. IL-1β and IL-1α synergize with TNF-α to enhance the production of NO and IFN-γ in murine models of malaria [@B81]. However, high levels of sustained IL-1β production in inflammatory diseases can induce a number of hematological abnormalities, including anemia [@B82], [@B83]. In murine models, administration of recombinant IL-1 can inhibit development of the pre-erythrocytic stages of malaria [@B84], protect against the development of cerebral malaria, and aid in controlling parasitemia [@B85]. Although several studies have reported elevated peripheral blood levels of circulating IL-1β levels in humans with severe malaria [@B86]-[@B88], an additional investigation failed to find significant changes in IL-1β levels in children with SMA [@B76]. Studies in Gambian children with falciparum malaria illustrated that IL-1α and TNF-α levels, measured upon admission to hospital, were positively correlated with venous blood lactate concentrations, which were approximately two-fold higher in fatal cases compared to survivors [@B89]. A study by our group investigating the role of IL-1β in the immunopathogenesis of SMA revealed that children with SMA had significantly lower levels of IL-1β than parasitized children without SMA [@B90]. In addition, haplotypes of IL-1β promoter polymorphisms that were associated with significantly greater risk of developing SMA were also associated with reduced IL-1β production, whereas those haplotypes associated with protection against SMA produced higher levels of IL-1β [@B90]. Thus, although sustained production of IL-1β can promote anemia [@B82], [@B83], it appears that \'high producing\' haplotypes of IL-1β provide protection against SMA.

Elevated levels of IL-6 in the peripheral blood of patients with severe *P. falciparum* malaria was recognized two decades ago [@B57]. This finding has since been corroborated by a number of studies showing elevated IL-6 levels in children with severe malaria [@B75], [@B76], [@B88]. An investigation in Gabonese children further demonstrated that peripheral blood mononuclear cells (PBMC) are a primary source of increased IL-6 production during acute malaria [@B91]. However, studies in murine models illustrate that IL-6 mediates protective immunity against the pre-erythrocytic stages of malaria by inducing IL-1β and TNF-α, and during the erythrocytic stage of disease by controlling parasitemia through boosting of specific immunoglobulin (Ig) G antibodies [@B84]. Experimental infections with *P. falciparum* in humans support these findings in that early IL-6 production is associated with protective effects [@B92]. Consistent with the protective effects of IL-6, lower circulating levels of IL-6 are associated with hyperparasitemia in Malian children with falciparum malaria [@B76]. Taken together, these studies support a protective role for IL-6 during the early stages of disease by controlling parasitemia. However, lack of control over the parasitemia and the resulting progression towards severe disease may explain the association between elevated levels of IL-6 and enhanced pathophysiology.

MIF was the first soluble mediator described in malaria [@B93], but has only recently been more fully explored in the context of malaria pathophysiology by our group and a number of others [@B47], [@B94]-[@B98]. MIF is a ubiquitous cytokine produced in response to pro-inflammatory stimuli by T cells [@B99], [@B100], monocytes/macrophages [@B101], and the anterior pituitary gland [@B102]. However, unlike most cytokines, MIF is constitutively expressed at high levels and stored in preformed vesicles, and as such can therefore be rapidly released without *de novo* gene expression [@B102], [@B103]. MIF has potent pro-inflammatory properties that are important for both innate and adaptive immune responses to bacterial and parasitic infections [@B100], [@B101], [@B104]-[@B106]. Murine models of malaria demonstrated that elevated MIF levels were associated with enhanced disease severity [@B107] with the MIF gene knock-out mice having less anemia and higher survival rates following infection with *P. chabaudi* compared to wild types [@B108].

Previous investigations in humans showed that MIF was elevated in intervillous blood during placental malaria [@B109], [@B110], thoracic blood vessels of Malawian children with cerebral malaria [@B111], and peripheral blood from Zambian children with acute malaria [@B108]. However, results from our laboratory were the first to show that elevated MIF protein (in circulation) and MIF transcripts (in PBMC) were associated with less severe forms of falciparum malaria [@B94]. We subsequently confirmed these results in a larger study of children (aged \<3 years, n=357) with *P. falciparum-*induced malarial anemia in western Kenya [@B47]. In the Kenyan cohort, circulating MIF concentrations declined with increasing severity of anemia and significantly correlated with peripheral blood leukocyte MIF transcripts. Interestingly, MIF concentrations in peripheral blood were not significantly correlated with reticulocyte responses in these children. However, multivariate regression modeling, controlling for age, gender, and parasitemia, demonstrated that elevated levels of PCM were significantly associated with both SMA and decreased MIF production. As a complement to the *in vivo* studies in children with malarial anemia, additional experiments were conducted in PBMC from malaria-naïve individuals which showed that phagocytosis of *Pf*Hz caused dysregulation in MIF production in a apoptosis-independent manner [@B47]. Taken together, investigations in Gabonese and Kenyan children with malarial anemia demonstrate that elevated levels of monocytic *Pf*Hz are associated with suppression of peripheral blood MIF production and enhanced severity of anemia.

Another pro-inflammatory mediator that appears important in conditioning the pathogenesis of SMA is IL-23. Although largely unexplored in the context of SMA, IL-23 is important in mediating the development of anemia in autoimmune diseases [@B112] and chronic inflammation [@B113]. IL-23 is composed of two subunits, p19 and p40 [@B114]. IL-23 shares a number of common properties with IL-12, including the p40 subunit [@B115], the ability to bind to the IL-12Rβ1 receptor [@B116], release from activated myeloid antigen presenting cells, promotion of a type 1 immune response [@B114]-[@B118], and suppression by both IL-10 [@B119], [@B120] and IL-12p40 homodimers [@B115], [@B121]. In addition to the common properties IL-23 shares with IL-12, there are also distinct immunological roles in that IL-23 acts on activated memory CD4+ T cells, while IL-12 promotes Th1 differentiation of naïve CD4+ T cells [@B114], [@B122]. Based on the common and distinct roles of IL-23 and IL-12, along with the well established importance of IL-12 in the pathogenesis of malarial anemia (discussed below in detail), we explored the relationships among these cytokines in Kenyan children with varying severities of malarial anemia [@B123]. Children with malarial anemia had increased peripheral blood levels of IL-23 and suppressed IL-12 relative to healthy controls. Additional experiments in cultured PBMC revealed that hemozoin caused a sustained induction of IL-23p19 transcripts over 72 h, while IL-12p40 and IL-10 transcripts peaked at 24 h, and rapidly declined thereafter. This line of investigation suggests that elevated IL-23 levels may be important in the pathogenesis of SMA, and that both IL-10 and IL-12 may regulate IL-23 production during an infection with *P. falciparum*.

Perhaps one of the most important innate inflammatory mediators in the pathogenesis of SMA is IL-12, a heterodimeric protein composed of 35 and 40 kDa subunits, and a prototypical cytokine of the type 1 immune response [@B124], [@B125]. IL-12 is secreted from dendritic cells, monocytes, and B-cells in response to bacterial cell wall components, intracellular pathogens, and CD40 ligation [@B124]-[@B126]. IL-12 stimulates production of IFN-γ and TNF-α from T-cells and natural killer (NK) cells [@B124], [@B125], thereby further augmenting type 1 responses. A number of cytokines and chemokines can promote IL-12 \[e.g., granulocyte macrophage-colony stimulating factor (GM-CSF) and IFN-γ\], while others decrease IL-12 production \[e.g., IL-4, IL-10, IL-11, IL-13, monocyte chemotactic protein (MCP)-1/CCL2, and TGF-β\] [@B125], [@B126]. As such, the overall ability of the innate immune response to generate IL-12 is an important event that mediates the development of malarial anemia.

Previous studies in the murine models showed that administration of recombinant IL-12 and chloroquine ameliorated blood-stage malaria and severe anemia, and induced immunity against re-infection [@B127]. Additional murine malaria studies demonstrated that deficient IL-12 production is associated with severe anemia and dyserythropoiesis [@B128]. The protective responses associated with IL-12 against blood-stage malaria appear to be due to increased IL-12 production from splenic macrophages and NK cells [@B129], [@B130] and the ability of IL-12 to stimulate antibody production [@B131]. Central to the role of IL-12 in malaria is its ability to act as a hematopoietic growth factor [@B132], [@B133]. In concert with IL-3, IL-12 along with IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-11 can bolster colony formation in dormant hematopoietic progenitors during times of cytopenic crisis [@B132], [@B133]. Consistent with this role, our previous studies in children with falciparum malaria showed that suppression of circulating IL-12 is associated with enhanced malarial anemia [@B77], [@B134]. Suppression of IL-12 in these children was also associated with increasing concentrations of *Pf*Hz-containing leukocytes [@B134]. Additional studies from our laboratories demonstrated that children with SMA have reduced IL-12 levels through a mechanism that involves, at least in part, phagocytosis of *Pf*Hz which promotes up-regulation of monocyte-derived IL-10 that, in turn, suppresses IL-12p40 subunits [@B135].

Anti-inflammatory Mediators
---------------------------

High levels of anti-inflammatory cytokines, such as IL-10, appear to provide protective effects against SMA by preventing the over-production of pro-inflammatory mediators. Anti-inflammatory cytokines are typically produced during the later stages of the innate immune response to *P. falciparum* in which they down-regulate the potentially pathogenic pro-inflammatory responses that are important for controlling parasitemia [@B136]. Previous investigations show that a low IL-10 to TNF-α ratio is associated with enhanced severity of malarial anemia [@B77], [@B137], suggesting that the timing and magnitude of pro-inflammatory cytokine production, relative to the anti-inflammatory cytokine response, is an important determinant of the clinical outcomes of malaria. Although plasma IL-10 levels are elevated in Malian children with SMA relative to healthy controls [@B76], studies in Ghana showed that plasma IL-10 levels were significantly lower in children with SMA compared to children with cerebral malaria, uncomplicated malaria, or moderate malarial anemia [@B138]. Additional studies have shown significant associations between circulating IL-10 levels and pigment-containing phagocytes in the peripheral blood [@B134], suggesting that malarial pigment plays an important role in governing the systemic pathology of malaria through up-regulation of IL-10 production.

TGF-β1 is an anti-inflammatory cytokine (and growth factor), which down-regulates the production of TNF-α and IL-10 and protects against severe murine malaria [@B139]. TGF-β appears to be important in malaria pathogenesis [@B86], [@B110], [@B140], and is attributed to both positive [@B141] and negative [@B141]-[@B143] effects on erythropoiesis. Previous studies from our group showed that TGF-β1 levels in peripheral blood are significantly reduced in Gabonese children with severe malaria [@B77]. However, studies in Burkina Faso revealed opposite effects in which severe childhood malaria was associated with increased plasma concentrations of TGF-β1 [@B144]. The reason for differing results may be due to the differences in malaria endemicity since the rural site in Lambaréné, Gabon, has a high level of *P. falciparum* transmission, whereas the urban region of Ouagadougou, Burkina Faso, is a mesoendemic area for *P. falciparum*. Alternatively, it is unclear whether or not \'platelet poor\' samples were used to measure TGF-β1 in the Burkina Faso study, an important consideration since platelets contain high levels of TGF-β1. A more recent study further supports the importance of the TGF-β family in malaria pathogenesis by showing that serum levels of the soluble form of the TGF-β co-receptor, endoglin (sEng or CD105/ TGF-βRIII), was significantly elevated in children with severe falciparum malaria [@B145]. In addition to TGF-β1, a recent investigation in Angolan children illustrates that polymorphic variability in TGF-β2 conditions susceptibility to the risk of progressing to cerebral malaria [@B146]. It remains to be definitively determined if TGF-β2 is also an important mediator of SMA pathogenesis.

Chemokines
----------

Chemotactic cytokines, or chemokines, are primarily known for their chemotactic properties, but also play important roles in immune activation, hematopoiesis, angiogenesis, and antimicrobial activities [@B147]. Burgmann et al. were the first to investigate chemokines in the context of malaria in 1995 by measuring the C-C chemokine, macrophage inflammatory protein (MIP)-1α/CCL3, and the C-X-C chemokine, IL-8/CXCL8, in the serum of acutely infected adult patients with *P. falciparum* infections in which they found a positive correlation between parasitemia and IL-8/CXCL8 [@B148]. A subsequent investigation revealed that Malian children with severe malaria had ten-fold higher concentrations of IL-8/CXCL8 compared to either healthy controls or individuals with uncomplicated malaria [@B76]. IL-8 is an important neutrophil activating chemokine that was also previously shown to be elevated in Thai patients with severe, non-fatal malaria [@B149]. Additional studies in Gabonese children and adults illustrated that higher plasma IL-8 levels were associated with acute malaria and a slow rate of cure after malaria chemotherapy [@B75].

It appears that phagocytosis of *Pf*Hz is an important signal for promoting chemokine production and/or suppression. For example, *Pf*Hz treatment of a bone marrow-derived murine cell line increased transcript levels of MIP-1α/CCL3, MIP-1β/CCL4, MIP-2/CXCL2, and MCP-1/CCL2 [@B150]. Concomitant studies from our group demonstrated that Gabonese children with severe malaria had elevated levels of MIP-1α/CCL3 and MIP-1β/CCL4 protein (measured in circulation) and transcripts (determined in *ex vivo* PBMC) [@B151]. Additional experiments in cultured PBMC from healthy, malaria-naïve donors revealed that *Pf*Hz promoted increased MIP-1α/CCL3 and MIP-1β/CCL4 production [@B151].

Regulated on activation, normal T-cell expressed and secreted (RANTES, CCL5) also appears to play a critically important role in the pathogenesis of SMA. RANTES is secreted by a number of cell types including monocytes, macrophages, fibroblasts, NK and T cells, and CD34+ hematopoietic progenitors [@B152]-[@B155]. RANTES protein is sequestered in the α-granules of platelets and is released by thrombin stimulated platelets [@B156], indicating that RANTES is involved in both innate and adaptive immune response. In addition, RANTES stimulates hematopoiesis, angiogenesis, cell proliferation, and development [@B157]. An earlier study by our group, which was the first to examine RANTES in the context of malaria, demonstrated that RANTES was suppressed in Gabonese children with severe malaria, at least in part, through *Pf*Hz-induced down-regulation of RANTES transcripts in PBMC [@B151]. The inherent ability to produce RANTES/CCL5 also appears important in conditioning susceptibility to severe malaria. For example, our investigation in Gabon revealed that healthy children with prior mild malaria produced significantly higher RANTES transcripts and protein than children with a history of severe malaria [@B151]. These investigations were then confirmed in Kenya where we showed that RANTES was significantly suppressed in children with SMA [@B29]. Suppression of RANTES in these children was also significantly associated with inefficient erythropoiesis and malaria-induced thrombocytopenia [@B29]. Subsequent studies from our laboratories determined that naturally acquired *Pf*Hz by monocytes promotes suppression of RANTES in children with malarial anemia through an IL-10-dependent mechanism [@B49]. Taken together, these findings suggest that thrombocytopenia may be an important source of reduced RANTES which appears to contribute to suppression of erythropoiesis in children with SMA.

Growth Factors
--------------

Since a number of growth factors influence the erythropoietic cascade, and SMA is clearly a disease process in which phagocytosis and lysis of RBCs necessitates the production of new RBCs to recover from anemia, growth factors will clearly emerge as critical determinants of clinical outcomes. However, the literature is largely lacking with respect to the importance of growth factors in conditioning the development of SMA. A time-course study in patients with *P. falciparum* malaria in Thailand showed that serum levels of granulocyte-colony stimulating factor (G-CSF) were significantly elevated in individuals with complicated disease on day 0 that then declined to within the normal range by day 7; G-CSF at day 0 was correlated with procalcitonin, parasite density, and erythropoietin [@B158]. Although not specifically examined in children with SMA, the potential negative consequences associated with over-production could certainly emerge since G-CSF has a negative impact on erythropoiesis [@B159]-[@B161].

GM-CSF is important for promoting erythropoiesis [@B162] and synergizes with TNF-α to increase the killing capabilities of neutrophils on blood-stage malaria parasites [@B163]. In addition, enhanced pathology in a murine model of malaria (characterized by parasitemia and anemia) was associated with elevated levels of erythropoietin (EPO), which were strongly correlated with the level of anemia, and negatively correlated with GM-CSF concentrations [@B164]. The influence that GM-CSF has on anemia outcomes in children with SMA remains to be determined.

As part of our investigations aimed at identifying genes/gene pathways that could play a role in the pathogenesis of SMA, we utilized gene expression profiling from pooled fractions of human PBMCs stimulated with *Pf*Hz. These experiments revealed that human stem cell growth factor \[SCGF, C-type lectin domain family member 11A, (CLEC11A)\] was up-regulated following treatment with *Pf*Hz [@B165]. SCGF is a hematopoietic growth factor, expressed primarily by myeloid cells and fibroblasts that possess burst-promoting activity for human bone marrow erythroid progenitors [@B166]. Human SCGF-α is a 323-amino acid protein, while SCGF-β is a 245-amino acid protein that results from cleavage of the conserved carbohydrate domain [@B167]. After determining the *in vitro* kinetics of SCGF expression in response to *Pf*Hz, we then examined circulating SCGF levels in Kenyan children with malarial anemia. SCGF levels in circulation and in cultured peripheral blood were significantly suppressed in children with SMA, with circulating SCGF levels being positively correlated with Hb concentration and the RPI [@B165]. SCGF was significantly lower in children with a suppressed erythropoietic response and in children with high levels of naturally acquired monocytic *Pf*Hz [@B165]. Our additional investigation showed that a novel SCGF promoter variant (-539C/T, rs7246355) was significantly associated with susceptibility to SMA and reduced erythropoietic responses with the \'high producing\' TT genotype protecting against development of SMA and suppression of erythropoiesis in parasitized children [@B168]. Taken together, these results illustrate that SCGF is an important mediator of SMA pathogenesis that may offer the potential for immunotherapy in future clinical trials.

Effector Molecules
------------------

As described above, the clinical outcomes of malaria are largely conditioned by the relative expression of inflammatory mediators. The relative timing and magnitude of pro- and anti-inflammatory cytokines, chemokines, and growth factors released into the inflammatory milieu have direct actions on the cellular response as well as the \'down-stream\' effector molecules that ultimately get produced. As such, effector molecules play a critical role in the pathogenesis of SMA. One important effector molecule in malaria is the toxic free radical, NO. NO and equimolar amounts of L-citrulline are generated by catalysis of L-arginine by the NO synthases (NOS) [@B169]. In the context of an acute inflammatory disease, such as malaria, much of the NO produced comes from the cytokine inducible isoform, nitric oxide synthase type 2 \[NOS2 or inducible NO synthase (iNOS)\] present in monocytes, macrophages, and neutrophils [@B170]. In general, pro-inflammatory cytokines (e.g. IL-12, IFN-γ, and TNF-α) increase NOS2-generated NO production, whereas anti-inflammatory cytokines (e.g. IL-10 and TGF-β) down-regulate NOS2 expression (for review see [@B171]). Although the role of NO in the pathogenesis of malaria has been debated for nearly a decade, it is apparent that NO is both protective and pathogenic. For example, NO is protective in that it has potent parasiticidal properties against *P. falciparum*[@B65] and can thereby limit parasitemia [@B172]. A protective effect is also illustrated by our previous investigation showing that healthy, malaria-exposed Gabonese children with a history of mild malaria have significantly higher levels of *ex vivo* PBMC NO production and NOS enzymatic activity than their age-matched cohort with a history of severe malaria [@B173]. However, our follow-up investigation in the same population revealed that *ex vivo* and *in vitro* NOS activity in PBMCs was significantly higher in children with malarial anemia in which there was an inverse association between NOS enzyme activity and hemoglobin levels [@B174]. Additional experiments confirmed that *Pf*Hz was an important source of NOS2 transcripts and NO production [@B174]. Thus, although NO serves an important role in controlling parasitemia, it is likely that sustained, high levels of NO production also promotes anemia. This premise is supported by the fact that generation of NO during a malarial infection can promote severe anemia through bone marrow suppression, dyserythropoiesis, and erythrophagocytosis (for review see [@B79]).

In addition to NO, reactive oxygen species (ROS) also appear to be both protective and pathogenic in human malaria. High levels of oxygen radical production are associated with accelerated clearance of parasitemia in Gabonese children with falciparum malaria [@B175]. In addition, ROS are important for controlling peripheral parasitemia in children with severe malaria [@B176]. A pathogenic role for ROS is illustrated by a study in Kenyan children showing that ROS cause damage to the erythrocytic membrane (demonstrated by measurement of α-tocopherol and polyunsaturated fatty acid levels in the erythrocyte membrane) [@B177]. A recent investigation in Indian children (\<15 years of age) infected with *P. falciparum* (in which the primary disease manifestation of severe malaria was SMA) revealed that severe malaria cases had significantly elevated markers of oxidant stress, including malondialdehyde, protein carbonyl, nitrite, ascorbic acid, and copper levels [@B178]. Although a wealth of data exists on the topic of free radicals in malaria, such a discussion is beyond the scope of this review. However, studies outlined here highlight both the protective and pathogenic roles of reactive nitrogen and oxygen intermediates.

Prostaglandin (PG)E~2~ is synthesized from arachidonic acid (AA) through the catalytic activity of cyclooxygenase (COX) enzymes also known as prostaglandin-H~2~ (PGH~2~) synthase, which exists in two isozymes: COX-1 (PGH synthase-1) and COX-2 (PGH synthase-2). Constitutively expressed COX-1 catalyses immediate biosynthesis of PGE~2~ and other prostanoids involved in physiological homeostasis, whereas inducible COX-2 catalyses delayed formation of PGE~2~and prostanoids involved in regulating the inflammatory response and immunity to invading pathogens [@B179]. Formation of PGH~2~, the committed step in prostanoid biosynthesis, promotes generation of primary prostanoids \[i.e., PGE~2~, PGH~2~, thromboxane A~2~, PGD~2~, PGF~2α~, and prostacyclin (PGI~2~) through the action of respective terminal prostanoid synthases [@B179]. Our previous study illustrates that intervillous blood mononuclear cell (IVBMC) PGE~2~ production is reduced in parasitemic women of all gravidae due, at least in part, to acquisition of intraleukocytic *Pf*Hz [@B180]. Additional studies from our group have shown that plasma bicyclo-PGE~2~ (a stable end metabolite of PGE~2~) and *ex vivo* PBMC COX-2 gene expression are significantly reduced in Gabonese children with severe malaria [@B181]. Studies in Tanzanian children also showed that suppression of systemic bicyclo-PGE~2~ production (measured in urine) was suppressed in children with cerebral malaria [@B182]. In addition, *in vitro* experiments in our laboratories revealed that reduced PGE~2~biosynthesis in children with falciparum malaria was largely due to inhibition of *de novo* COX-2 transcripts following phagocytosis of *Pf*Hz by monocytes [@B183], [@B184]. Further investigation of the role of prostaglandins in childhood malaria showed that suppression of PGE~2~by *Pf*Hz and commonly used antipyretics to treat the malarial fever promoted over-production of TNF-α, an event associated with enhanced malaria pathogenesis [@B183], [@B184].

12. *In vitro* Models for Investigating Suppression of Erythropoiesis in Malarial Anemia {#Section12}
========================================================================================

*In vitro* studies have shown that *Pf*Hz directly (or in synergy with TNF-α) inhibits erythroid cell development [@B46]. In addition to inducing erythropoiesis-inhibiting cytokines, *Pf*Hz has direct effects on the erythropoietic cascade through its ability to cause apoptosis of erythroid precursor cells via oxidative stress [@B185]. We recently developed an *in vitro* model of erythropoiesis using CD34+ stem cells isolated from human peripheral blood to investigate the effects of inflammatory mediators on erythroid development [@B186]. This model showed that *Pf*Hz only slightly suppressed erythroid cell proliferation and maturation, marked by decreased expression of glycophorin A (GPA) [@B186]. However, the addition of *Pf*Hz-stimulated PBMC-conditioned media (*Pf*Hz-CM), recombinant TNF-α, and NO donors significantly inhibited erythroid cell proliferation [@B186]. The decreased proliferation witnessed in cells treated with *Pf*Hz-CM and NO was accompanied by increased apoptosis of erythropoietin-stimulated CD34+ cells [@B186]. Interestingly, the addition of NO donors significantly inhibited erythroid cell maturation, whereas TNF-α failed to impact on maturation. These results demonstrate that *Pf*Hz suppresses erythropoiesis by acting directly on erythroid cells, and to a greater extent, through indirect effects in which phagocytosis of *Pf*Hz generates inflammatory mediators which have adverse effects on erythroid development.

13. Conclusion {#Section13}
==============

Studies outlined here support a model in which the pathogenesis of SMA is largely driven by dysregulation in pro- and anti-inflammatory cytokines, chemokines, growth factors, and effector molecules. Altered patterns of these innate inflammatory mediators is due, at least in part, to the phagocytosis of *Pf*Hz by monocytes, resident macrophages (including those in bone marrow), and neutrophils. The mechanisms that lead to the profoundly low Hb concentrations witnessed in children with SMA are due to hemolysis and phagocytosis of parasitized and non-parasitized RBCs, and to a large extent, by suppression of erythropoiesis that is driven by *Pf*Hz-generated dysregulation in innate inflammatory mediators. While it is clear that overcoming the global burden of SMA will continue to present a serious challenge, it is our hope that gaining an improved understanding of pathogenic events that cause suppression of erythropoiesis, particularly dysregulation in innate immunity, may offer future treatment strategies to combat the unacceptable rates of morbidity and mortality associated with SMA.

![***Proposed Model of Dysregulation in Innate Immune Responses in Severe Malarial Anemia***. Based on concomitant measurement of innate inflammatory mediators (using multiplex technologies) in children with varying severities of malarial anemia, we developed a model to describe how dysregulation in innate inflammatory mediators promotes suppression of erythropoiesis in children with SMA. Central to the model is the fact that phagocytosis of hemozoin (*Pf*Hz) by monocytes is one of the primary causes of altered production of innate inflammatory mediators. Elevated inflammatory mediators are shown in green text, while those that are decreased in children with SMA are shown in red text. Solid lines indicate positive signaling (up-regulation), whereas dashed lines indicate suppression (down-regulation). Children with SMA have decreased levels of IL-12 in response to ingestion of parasitized red blood cells (pRBC) and/or hemozoin by monocytes. Suppression of IL-12 in children with SMA is due to *Pf*Hz-induced IL-10 over-production. Children with SMA have increased circulating levels of TNF-α, IFN-γ, IL-6, MIP-1α, and MIP-1β. Although TNF-α can induce PGE~2~ and nitric oxide (NO), these effector molecules are suppressed in children with SMA. Suppression of PGE~2~ allows over-production of TNF-α, which is associated with enhanced severity of anemia. In addition, MIF is suppressed in children with falciparum malaria, an event associated with phagocytosis of *Pf*Hz by monocytes, and enhanced severity of anemia. Circulating levels of IFN-α, IL-1β, RANTES, and SCGF are also decreased in children with SMA. Reduced production of these innate inflammatory mediators, along with increased TNF-α, IL-6, MIP-1α and MIP-β, likely contribute to the development of SMA by suppressing the erythropoietic response. Lastly, although the reduced NO and reactive oxygen species (ROS) generation reported in children with falciparum malaria may promote ineffective parasite killing and, thereby, prolong parasitemia, children with malarial anemia have elevated levels of NO and ROS that can directly inhibit erythropoiesis.](ijbsv07p1427g01){#F1}
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